Last reviewed · How we verify

PYROVALERONE

FDA-approved withdrawn Small molecule Quality 10/100

Pyrovalerone is a marketed drug that operates by blocking the sodium-dependent dopamine transporter, enhancing dopamine availability in the brain. Its key competitive advantage lies in its unique mechanism of action, distinct from many off-patent generics and some patent-protected competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePYROVALERONE
TargetSodium-dependent dopamine transporter, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: